January 16, 2024 · Form 4 insider transaction
Adjuvant Global Health Technology Fund, L.P. sold 15,907 shares of AN2 Therapeutics, Inc. at $19.65 per share, a transaction worth $312.6K. The trade was recorded as open-market sale and disclosed on an SEC Form 4, filed 2 days after the transaction.
Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. ("AGHT Fund DE"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. Kabeer Aziz, a member of the Issuer's board of directors, is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.